Navigation Links
Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results

LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) will host a teleconference call today at 2:30 p.m. EST to review its drug development programs and financial results for the third quarter of 2008. Duska's chief executive officer, James S. Kuo, MD, MBA, will host the call and there will be a question-and-answer session immediately afterward.

To participate in the teleconference, please call toll-free 800.895.0198 (direct dial 785.424.1053) five minutes prior to the scheduled starting time in order to register for the call. A replay of the call will be available after its completion for ten days at 800.283.8217 (direct dial 402.220.0868).

"We have made remarkable progress in our two lead drug development programs this past quarter as we prepare for a Phase 2 trial for one compound and a Phase 3 trial for the other early next year," said Dr. Kuo. "In addition, we strengthened the intellectual property position around our ATPotent program through licenses with several inventors."

    Highlights of accomplishments included:

    -- Submission of a pivotal Phase 3 ATPace clinical trial protocol for
       review under a Special Protocol Assessment (SPA) procedure with the
       U.S. Food and Drug Administration (FDA).

       Subject to securing an agreement with the FDA, Duska intends to
       initiate a single, prospective, double-blind, placebo-controlled and
       randomized Phase 3 clinical trial with ATPace, its lead product. The
       trial will be aimed at demonstrating clinical safety and efficacy of
       ATPace in treating emergency room patients presenting with paroxysmal
       supraventricular tachycardia (PSVT).  PSVT is a condition characterized
       by a rapid, regular heart rate originating in the atria, which affects
       approximately 570,000 patients in the United States alone; in addition,
       89,000 new cases per 
SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
2. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
3. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
4. Duska Therapeutics Obtains Standard & Poors Listing
5. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
6. Arete Therapeutics Closes $16.7 Million in Final Tranche of Its Series A Financing
7. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
8. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
9. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
10. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
11. Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
(Date:7/6/2015)... 2015  Approximately 1% of the population inherits a ... These individuals are three times more likely to develop ... of the nation,s leading medical journals by researchers from ... Photo - ... roseola (also known as "sixth disease") and occasional seizures ...
(Date:7/6/2015)... ... July 06, 2015 , ... Discovery of new biomarkers for ... drivers of the global molecular diagnostics market. BCC Research reveals in its new ... companion diagnostic tests will increase demand for inexpensive and accurate tests for genetic ...
(Date:7/6/2015)... SUNNYVALE, Calif. , July 6, 2015  Viveve Medical, ... announced that Patricia Scheller , Viveve,s Chief Executive Officer, ... present live at on July 9, 2015. , ... 9, 2015 , , , , TIME:     ... , LINK: , , ,   , ...
(Date:7/6/2015)... LOS ANGELES , July 6, 2015 ... the establishment of an agreement with Novella Clinical ... of ICT-107 in patients with newly diagnosed glioblastoma. Novella ... clinical trial services to small to mid-sized oncology companies. ... clinical sites in the US, Europe ...
Breaking Biology Technology:Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3Viveve to Webcast Live at 2Viveve to Webcast Live at 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... layoff announcements from more than a dozen employers in health care, employment ... past month it seemed like no one was searching for those new ... ... continues in the health care field, with an average of 30,000 jobs ...
... Ranked First Among Nation,s Health Insurers, VIRGINIA BEACH, ... ) has been named one of America,s Best Places ... country,s health insurers -- in a,survey conducted by Modern ... of its kind conducted by Modern,Healthcare, was open to ...
... ... Income per Share - $0.13 vs. $0.07 in Q3 2007 - an ... increase of 85.7% Q3 2008 Operating Income margin of ... million in Q3 2007, PHILADELPHIA, Oct. 30 eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), a leading ...
Cached Biology Technology:The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 3AMERIGROUP Corporation Named One of Best Places to Work in Healthcare 2eResearchTechnology Reports Third Quarter 2008 Results 2eResearchTechnology Reports Third Quarter 2008 Results 3eResearchTechnology Reports Third Quarter 2008 Results 4eResearchTechnology Reports Third Quarter 2008 Results 5eResearchTechnology Reports Third Quarter 2008 Results 6eResearchTechnology Reports Third Quarter 2008 Results 7eResearchTechnology Reports Third Quarter 2008 Results 8eResearchTechnology Reports Third Quarter 2008 Results 9eResearchTechnology Reports Third Quarter 2008 Results 10
(Date:7/2/2015)... -- Fingerprint Cards has received an order for ... the distributor World Peace Industrial Group (WPI), part of WPG ... Asia . Deliveries are planned to take place during ... smartphone manufacturers in Asia . The order ... guidance of approximately 2,200 MSEK for 2015. Jörgen ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/26/2015)... 2015 ATL Technology, LLC, a top provider of ... single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Costa Rica ). This acquisition will incorporate ... with ATL Technology,s existing facility in Costa Rica ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... have hypothesized that the fetus can be exposed to ... the mother has been exposed, and this may have ... eczema and asthma) later in an infant’s life. However ... to detect antigen-specific T cells in cord blood. Recently, ...
... discovered 24 species believed to be new to science, ... amphibians, fish and insects. , Presented in a report ... led by Conservation International’s Rapid Assessment Program (RAP) and ... exploring unknown regions such as Suriname’s rainforest to assess ...
... dormant bacterial spores, researchers have revealed through atomic force ... cell wall that accompany the transformation from a spore ... Bacillus (rod-shaped bacteria) cells initiate a series of genetic, ... of metabolically dormant spores. They can remain dormant for ...
Cached Biology News:Researchers find 24 species believed new to science in Suriname rainforest 2Researchers track how spores break out of dormant state 2
... Methylated Protein Molecular Weight Markers, 37 kBq, ... molecular weight determination of the sample on ... monitoring of band migration in the gel ... the [14C] version without Rainbow-labeling is 0.37-3.7 ...
NM522 contains an F episome, which is required for production of ssDNA and for blue/white color selection. To maintain the F, NM522 should be grown on minimal (M-9) medium....
... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
... 1 EA. Ultrospec 6300 pro ... of the Pharmacopoeia in terms of instrument ... of being able to be used for ... and excellent scanning capability., *Press to read ...
Biology Products: